Using Inhalable Nanoparticles to Treat COPD, a Chronic Lung Disease

Using inhalable nanoparticles to deliver drugs to the lungs could help treat chronic obstructive pulmonary disease (COPD). In mice with signs of the condition, treatment improved lung function and reduced inflammation.

COPD causes the airways in the lungs to gradually narrow and stiffen, blocking airflow and blocking mucus drainage. As a result, mucus builds up in the lungs, attracting bacterial pathogens that further worsen the disease.

This thick layer of mucus also traps drugs, making it difficult to treat infections. So, Zhu Junliang Researchers at China's Dongzhou University have developed inhalable nanoparticles that can penetrate mucus and deliver drugs deep into the lungs.

The researchers constructed hollow nanoparticles from porous silica and loaded them with an antibiotic called ceftazidime. A shell of negatively charged compounds surrounding the nanoparticles blocked the pores and prevented the antibiotic from leaking. This negative charge also helps the nanoparticles penetrate mucus. The slight acidity of the mucus then changes the charge on the shell from negative to positive, opening the pores and releasing the drug.

Researchers used an inhalation spray containing nanoparticles to treat bacterial lung infections in six mice with signs of COPD. A similar number of animals received antibiotics only.

On average, mice treated with nanoparticles had about 98 percent fewer pathogenic bacteria in their lungs compared to mice given antibiotics alone. They also had fewer inflammatory molecules in their lungs and less carbon dioxide in their blood, indicating better lung function.

These findings suggest that nanoparticles could improve drug delivery to people with COPD and other lung diseases such as cystic fibrosis, where thick mucus makes infections difficult to treat. It has said. vincent rotello from the University of Massachusetts Amherst was not involved in the study. However, it is unclear whether these nanoparticles are cleared from the lungs. “If you have a delivery system that accumulates over time, that's a problem,” he says.